title: Associations of Circulating PYY3-36Concentrations with Metabolic Syndrome in Extremely Obese Subjects.
abstract: The gut hormone peptide YY3-36(PYY3-36) plays major roles in regulation of appetite and energy metabolism, mediates beneficial effects of bariatric surgery, and may be a potential weight-reducing and glucose-modulating therapy. Obesity may influence the metabolic expression of circulating PYY3-36and metabolic markers. We studied the relationship of PYY3-36concentrations with metabolic syndrome (MetSyn) components, lipids, insulin resistance, and inflammatory biomarkers in subjects with extreme obesity.
  
  
  
  We measured MetSyn components and PYY3-36, lipids, hormones, homeostasis model assessment (HOMA) index, and inflammatory biomarkers in consecutively referred patients (180 women and 111 men) aged 18-78 years with body mass index (BMI) ≥40 kg/m2. Associations of PYY3-36to components, insulin resistance, and biomarkers were examined with partial correlations and linear regression.
  
  
  
  PYY3-36concentrations were not related to MetSyn components, HOMA index, or to inflammatory biomarker or leptin concentrations. PYY3-36concentrations correlated with systolic blood pressure (r = 0.21; P < 0.0001) after adjustment for age and gender. In linear regression analysis, PYY3-36concentrations were associated with systolic blood pressure after adjustment for age, gender, and central obesity in the entire sample (Beta 0.21; 95% CI 0.09-0.34) as well as in subjects not taking blood pressure-lowering medication (Beta 0.19; 95% CI 0.04-0.36). These associations were not statistically significant in the small subset of participants (22%) with type 2 diabetes.
  
  
  
  In extremely obese patients, fasting PYY3-36concentrations were linked to systolic blood pressure, but not to other components of MetSyn, suggesting divergence between pathways of blood pressure and glucose/body weight regulation. However, this finding will need to be further investigated.
authors: 1 Section for Preventive Cardiology, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital , Oslo, Norway .
authors: Sasa
authors: S
authors: Dusanov
authors: 2 Rimfrost AS , Fosnavåg, Norway .
authors: Kari
authors: K
authors: Brandal
authors: 1 Section for Preventive Cardiology, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital , Oslo, Norway .
authors: Eli
authors: E
authors: Heggen
authors: 1 Section for Preventive Cardiology, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital , Oslo, Norway .
authors: Serena
authors: S
authors: Tonstad
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D008875:Middle Aged; D009767:Obesity, Morbid / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D010446:Peptide Fragments / Q000097:blood* / Q000502:physiology; D019894:Peptide YY / Q000097:blood* / Q000502:physiology; D055815:Young Adult
chemical_list: D015415:Biomarkers; D018836:Inflammation Mediators; D008055:Lipids; D010446:Peptide Fragments; D019894:Peptide YY; C061785:peptide YY (3-36)
keywords: PYY3-36; diabetes; metabolic syndrome; obesity